Multiple Sclerosis, Relapsing-Remitting: all 615 studies
Page 7 of 7. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.
- Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMSTerminatedNCT00202995Phase 4
- Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple SclerosisCompletedNCT00200655Phase 3
- Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MSCompletedNCT00168766Phase 4
- AVONEX® Combination Trial - "ACT"CompletedNCT00112034Phase 4
- Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) SubjectsWithdrawnNCT00101959Phase 4
- BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) PatientsCompletedNCT00099502Phase 3
- Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00097760Phase 2
- Three Months Treatment With SB683699 In Patients With Relapsing Multiple SclerosisCompletedNCT00097331Phase 2
- A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple SclerosisCompletedNCT00097188Phase 2
- Safety of RG2077 in Patients With Multiple SclerosisCompletedNCT00076934Phase 1
- Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT00071838Phase 2
- Treatment of Multiple Sclerosis Using Over the Counter InosineCompletedNCT00067327Phase 2
- A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple SclerosisTerminatedNCT00035529Phase 2
- Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple SclerosisCompletedNCT00030966Phase 3
- Safety and Efficacy of Natalizumab in the Treatment of Multiple SclerosisCompletedNCT00027300Phase 3